Experts: Tread Carefully In New, More Ambiguous Patent Environment
This article was originally published in The Gray Sheet
Executive Summary
Device companies seeking to obtain a patent must act conservatively in the wake of an uncertain legal environment created by recent Supreme Court patent decisions.
You may also be interested in...
Supreme Court Gives Some Relief, But Leaves Open Questions For Dx Patents
Diagnostics and biotech firms praised a June 28 Supreme Court opinion for allowing judges some flexibility in ruling on the patent-eligibility of "process" claims, but patent attorneys warn that many issues remain unsettled
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.